Clinical trial
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
NCT00412594 · M.D. Anderson Cancer Center, Other · Recruiting
Key facts
| NCT number | NCT00412594 |
|---|---|
| Title | Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia |
| Official title | Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia |
| Intervention type | Biological, Drug, Other |
| Interventions | Cladribine, Laboratory Biomarker Analysis, Rituximab |
| Enrollment | 150 |
| Start date | Jun 10, 2004 |
| Primary completion | Jun 30, 2027 |
| Completion | Jun 30, 2027 |
| First posted | Dec 18, 2006 |
| Last update posted | Dec 22, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: